相关实验视频

Updated: Sep 14, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

作为差异化甲状腺癌治疗方法的DNA-PKcs抑制

Shu-Fu Lin, Wei-Yi Chen, Chuen Hsueh

Endocrine-related cancer

|July 21, 2025

概括

取决于DNA的蛋白激酶催化子单元 (DNA-PKcs) 抑制剂对差异化甲状腺癌 (DTC) 治疗有希望. M3814作为单一药物和组合药物的有效性得到证明,抑制瘤生长,并提供了一种新的治疗途径.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症治疗方法癌症治疗方法

背景情况:

依赖DNA的蛋白激酶催化子单元 (DNA-PKcs) 是一种对癌细胞过程至关重要的血清氨酸-三氨酸激酶.
DNA-PKcs被确定为差异化甲状腺癌 (DTC) 的潜在治疗点.

研究的目的:

在差异化甲状腺癌 (DTC) 模型中评估DNA-PKcs抑制剂M3814的疗效.
评估M3814作为单一药物和用于DTC的组合治疗.

主要方法:

在四个DTC细胞系 (TPC1,K1,FTC-133,FTC-238) 上进行了体外细胞毒性测试.
进行了细胞周期分析,以确定M3814对DTC细胞增殖的影响.
在体内研究中,使用K1瘤模型进行单一治疗,并使用FTC-133异种移植模型与伦瓦提尼布联合治疗.

主要成果:

在所有测试的DTC细胞系中,M3814诱导了剂量依赖的细胞毒性.
M3814治疗导致DTC细胞中的S相细胞周期停止.
单独治疗M3814抑制了K1瘤的生长;在FTC-133异种移植模型中,与伦瓦提尼布的组合显示出协同效应和更高的疗效.

结论:

M3814显示出作为差异化甲状腺癌的治疗剂的显著潜力.
M3814证明了作为独立治疗和与其他疗法相结合的疗法的有效性,例如伦瓦提尼布用于DTC.

关键词:

这就是DNA-PKcscs.M381414 这是一个很大的问题.组合疗法治疗组合治疗.有差异化的甲状腺癌.这是一种激酶抑制剂 (kinase inhibitor).

更多相关视频

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...